Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%) Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CIS LEGEND trial pivotal coh
(Financial Post, 2025-11-11T12:34:48Z)